Gossamer Bio, Inc. (GOSS)
NASDAQ: GOSS · Real-Time Price · USD
0.696
+0.031 (4.66%)
At close: Nov 22, 2024, 4:00 PM
0.690
-0.005 (-0.78%)
After-hours: Nov 22, 2024, 5:39 PM EST
Company Description
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States.
The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.
It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds.
The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017.
Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
Gossamer Bio, Inc.
| Country | United States |
| Founded | 2015 |
| IPO Date | Feb 8, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 135 |
| CEO | Faheem Hasnain |
Contact Details
Address: 3013 Science Park Road, Suite 200 San Diego, California 92121 United States | |
| Phone | 858 684 1300 |
| Website | gossamerbio.com |
Stock Details
| Ticker Symbol | GOSS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001728117 |
| CUSIP Number | 38341P102 |
| ISIN Number | US38341P1021 |
| Employer ID | 47-5461709 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Faheem Hasnain | Co-Founder, Chief Executive Officer, President and Chairman |
| Bryan Giraudo | Chief Operating Officer and Chief Financial Officer |
| Robert P. Smith | Chief Commercial Officer |
| Jeff Boerneke | General Counsel and Secretary |
| Deanna Weber | Senior Vice President of Human Resources |
| Dr. Richard Aranda M.D. | Chief Medical Officer |
| Caryn L. Peterson | Executive Vice President of Regulatory Affairs |
| Matt Cravets | Senior Vice President of Biometrics |
| Dr. Lisa Elizabeth Nolan Ph.D. | MD and President of Gossamer Bio Ireland |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | 8-K | Current Report |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Sep 13, 2024 | 8-K | Current Report |
| Aug 12, 2024 | 8-K | Current Report |
| Aug 12, 2024 | 10-Q | Quarterly Report |
| Aug 2, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jul 18, 2024 | 8-K | Current Report |
| Jun 10, 2024 | 8-K | Current Report |